104 results on '"Kosinski, M."'
Search Results
2. EPH234 Cancer-Related Disease Trauma: A Public Health Crisis
3. PCR58 Participant Reinterpretation of Health States: A Think-Aloud Study of Decision-Making Strategies in Discrete Choice Experiments with the SF-6DV2
4. POSC381 Derivation of Interpretation Thresholds for the SF-36V2® Health Survey (SF-36V2) in Rheumatoid Arthritis
5. POSA378 Derivation of Interpretation Thresholds for the Rheumatoid Arthritis Symptoms and Impact Questionnaire (RASIQ) and Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-FATIGUE) Scale
6. PNS111 Development of the SF-6DV2 Health Utility Survey: Content Validity and Patient Preference
7. PMU98 A Literature Review of the Impact of Disease Outbreaks and Natural Disasters on Health-Related Quality of Life
8. Usability of daily SF36 questionnaires to capture the QALD variation experienced after vaccination with AS03A-adjuvanted monovalent influenza A (H5N1) vaccine in a safety and tolerability study
9. PSY3 PSYCHOMETRIC VALIDATION OF FACIT-FATIGUE IN SYSTEMIC LUPUS ERYTHEMATOSUS
10. A Perspective on Asthma Control Through the Asthma Control Test (ACT)
11. Consistency of Psychometric Properties of the ACT Across Randomized Clinical Trial Designs
12. Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis and F508del/F508del-CFTR: patient-reported outcomes in a Phase 3, randomised, controlled trial (EVOLVE)
13. Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a Phase 3, randomised, controlled trial (EXPAND)
14. S68 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients with cystic fibrosis homozygous for F508del-CFTR: patient-reported outcomes in a phase 3 randomized, controlled trial (EVOLVE)
15. S67 Effects of tezacaftor/ivacaftor (TEZ/IVA) treatment in patients heterozygous for F508del-CFTR and a residual function mutation: patient-reported outcomes in a phase 3 randomized, controlled trial (EXPAND)
16. Reply to Sharp et al.: Psychological targeting produces robust effects
17. Reply to Eckles et al.: Facebook’s optimization algorithms are highly unlikely to explain the effects of psychological targeting
18. A Standardized Cognitive Interview Approach to Ensure Quality in Caregiver-Recorded Videos of Duchenne Muscular Dystrophy Patients’ Physical Function for Clinical Evaluation
19. Psychological targeting as an effective approach to digital mass persuasion
20. Cognitive Debriefing Of The Dmd-Specific Measures Of Physical Functioning – Caregiver Questionnaire
21. Development of novel observer-reported outcome assessments in clinical trials of patients with Duchenne muscular dystrophy
22. SAT0126 Mental health benefits associated with reduction in disease activity among rheumatoid arthritis patients: a systematic review of the literature
23. FRI0133 Is there incremental mental health burden associated with rheumatoid arthritis?
24. A Cross-National Comparison Of The Effect Of Age And Gender On Health-Related Quality Of Life (Hrql)
25. AB0251 Early Onset of Benefit by Patient-Reported Outcomes (PROs) with Sarilumab Treatment in RA
26. 138 Impact of pulmonary exacerbations (PEx) on health-related quality of life (HRQoL) assessed by the Cystic Fibrosis Questionnaire-Revised (CFQ-R) in TRAFFIC and TRANSPORT
27. FRI0058 Improvements in Health Related Quality of Life (HRQOL) Reported by Rheumatoid Arthritis (RA) Patients in a Randomized Controlled Trial [RCT] of Sarilumab [Mobility] that Met or Exceeded the Patient Acceptable Symptom State [Pass] And Normative Values
28. New Aspects of Complexation of Technetium with DTPA Ligand
29. Comparison Of The Burden Of Ibs With Constipation On Health-Related Quality Of Life (Hrqol), Work Productivity, And Health Care Utilization To Asthma, Migraine, And Rheumatoid Arthritis In The Us, Uk, And France
30. P.7.b.011 Validation of the Weiss Functional Impairment Rating Scale – Parent Report Form in attention deficit/hyperactivity disorder
31. The French-Canadian validation of a disease-specific, patient-reported outcome measure for lupus
32. SAT0020 Cross Cultural Adaptation and Validation of Lupuspro in Southern Chinese Patients with Systemic Lupus Erythematosus: Table 1.
33. FRI0178 Estimated Medical Expenditures among Patients with Rheumatoid Arthritis Undergoing Treatment with Tofacitinib, an Oral Janus Kinase Inhibitor
34. 37: 152/161Tb-DOTA-RM6 biodistribution studies in prostate cancer bearing SCID mice and 149Tb sources from CERN-MEDICIS
35. Postpartum reversibility of impaired incretin effect in gestational diabetes mellitus
36. AB0505 Enhanced improvement in physical functioning with secukinumab treatment among RA patients: An application of IRT methodology
37. AB0507 Health-related quality of life (HRQOL) benefits associated with reductions in disease activity and pain severity among rheumatoid arthritis (RA) patients treated with secukinumab
38. AB0506 Enhanced improvement in fatigue from RA treatment with secukinumab: An application of IRT methodology
39. AB0504 Association between health-related quality of life (HRQOL) and ACR improvement among rheumatoid arthritis (RA) patients treated with secukinumab
40. Spanish LupusPRO: cross-cultural validation study for lupus
41. Qualitative validation of the FACIT-Fatigue scale in systemic lupus erythematosus
42. Cross-cultural validation of a disease-specific patient-reported outcome measure for lupus in Philippines
43. PSY39 Validation of the Lupus Impact Tracker (LIT), a Patient-Reported Outcome (PRO) Tool, in a Prospective Multicenter Longitudinal Study of Systemic Lupus Erythematosus (SLE) Patients
44. Can Well-Being be Measured Using Facebook Status Updates? Validation of Facebook’s Gross National Happiness Index
45. 18F-FLT and 125I-IdUrd uptake increase in human tumour cell lines induced by the thymidylate synthase inhibitor FdUrd
46. PRM25 PSYCHOMETRIC COMPARIBILITY OF SINGLE ITEM AND GRID FORM ADMINISTRATION OF THE SF-36V2™ HEALTH SURVEY
47. PSY36 DEVELOPMENT OF THE LUPUS IMPACT TRACKER: A TOOL FOR PATIENTS AND PHYSICIANS TO ASSESS AND MONITOR THE IMPACT OF SYSTEMIC LUPUS ERYTHEMATOSUS (SLE)
48. PSY35 VALIDATION OF THE LUPUS IMPACT TRACKER
49. Design-for-Six-Sigma for Development of a Bioprocess Quality-by-Design Framework
50. Further Validation and Definition of the Psychometric Properties of the Asthma Impact Survey
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.